Please login to the form below

Not currently logged in
Email:
Password:

Lilly bolsters its oncology team

Kimberly Blackwell is appointed VP early phase development, immuno-oncology

Eli Lilly and Company has strengthened its oncology team with the addition of Kimberly Blackwell, who joins the pharma group as its new vice president of early phase development and immuno-oncology.

Blackwell currently serves as a professor of medicine and assistant professor of radiation oncology at Duke University Medical Center, and she is also the co-director of the Duke women’s cancer programme, associate director for strategic relations for the Duke Cancer Institute among other roles.

Sue Mahon, senior vice president and president of Lilly Oncology, said: “We are pleased and honoured to welcome Dr Blackwell to Lilly, she is a highly regarded for her leadership in cancer research, especially metastatic breast cancer, where she has led programmes that resulted in numerous ground-breaking regulatory approvals.

“Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop and advance novel treatments for people living with cancer.”

15th January 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics